Daniel Braas,Ethan Ahler,Brenna Tam,David Nathanson,Mirielle Riedinger,Matthias R. Benz,Kathleen B. Smith,Fritz C. Eilber,Owen N. Witte,William D. Tap,Hong Wu,Heather R. Christofk

Abstract:PDF file - 163, Supplemental Figure 1: Serially passaged liposarcoma xenograft tumors derived from primary tumors and xenograft tumors derived from liposarcoma cell lines both exhibit similar 18F-FDG uptake by PET. Supplemental Figure 2: High grade liposarcomas exhibit variable FDG uptake by PET. Supplemental Figure 3: Nutrient concentrations in medium and metabolites consumed by liposarcoma cell lines. Supplemental Figure 4: Glucose and glutamine consumption rates and lactate production rates are similar in three liposarcoma cell lines

Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure 9 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figures 6-8 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figures 1-4 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure Legends 1-2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure 1 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Supplementary Figure Legends 1-4, Methods from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 4 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 5 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Supplementary Figure 3 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer

Supplementary Figure Legends from RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Figure 2 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer